T2DM causes an approximately 1.7-fold enhancement in the development of HCC and malignancies other than HCC in HCV-positive patients treated with IFN (Hepatology)
Diabetes News Service
T2DM causes an approximately 1.7-fold enhancement in the development of HCC and malignancies other than HCC in HCV-positive patients treated with IFN (Hepatology)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales